Hepion Pharmaceuticals
HEPA
#10815
Rank
$14.62 M
Marketcap
$0.12
Share price
3.22%
Change (1 day)
69.57%
Change (1 year)

Hepion Pharmaceuticals - 10-Q quarterly report FY2026 Q3


Text size:
falseQ3--12-31000158377100015837712026-01-012026-09-3000015837712026-11-0800015837712026-09-3000015837712025-12-310001583771us-gaap:SeriesAPreferredStockMember2026-09-300001583771us-gaap:SeriesAPreferredStockMember2025-12-310001583771us-gaap:SeriesCPreferredStockMember2026-09-300001583771us-gaap:SeriesCPreferredStockMember2025-12-3100015837712026-07-012026-09-3000015837712025-07-012025-09-3000015837712025-01-012025-09-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2025-12-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2025-12-310001583771us-gaap:CommonStockMember2025-12-310001583771us-gaap:TreasuryStockCommonMember2025-12-310001583771us-gaap:AdditionalPaidInCapitalMember2025-12-310001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001583771us-gaap:RetainedEarningsMember2025-12-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2026-03-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2026-03-310001583771us-gaap:CommonStockMember2026-03-310001583771us-gaap:TreasuryStockCommonMember2026-03-310001583771us-gaap:AdditionalPaidInCapitalMember2026-03-310001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001583771us-gaap:RetainedEarningsMember2026-03-3100015837712026-03-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2026-06-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2026-06-300001583771us-gaap:CommonStockMember2026-06-300001583771us-gaap:TreasuryStockCommonMember2026-06-300001583771us-gaap:AdditionalPaidInCapitalMember2026-06-300001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300001583771us-gaap:RetainedEarningsMember2026-06-3000015837712026-06-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2024-12-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2024-12-310001583771us-gaap:CommonStockMember2024-12-310001583771us-gaap:AdditionalPaidInCapitalMember2024-12-310001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001583771us-gaap:RetainedEarningsMember2024-12-3100015837712024-12-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2025-03-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2025-03-310001583771us-gaap:CommonStockMember2025-03-310001583771us-gaap:AdditionalPaidInCapitalMember2025-03-310001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001583771us-gaap:RetainedEarningsMember2025-03-3100015837712025-03-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2025-06-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2025-06-300001583771us-gaap:CommonStockMember2025-06-300001583771us-gaap:AdditionalPaidInCapitalMember2025-06-300001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001583771us-gaap:RetainedEarningsMember2025-06-3000015837712025-06-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2026-01-012026-03-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2026-01-012026-03-310001583771us-gaap:CommonStockMember2026-01-012026-03-310001583771us-gaap:TreasuryStockCommonMember2026-01-012026-03-310001583771us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001583771us-gaap:RetainedEarningsMember2026-01-012026-03-3100015837712026-01-012026-03-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2026-04-012026-06-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2026-04-012026-06-300001583771us-gaap:CommonStockMember2026-04-012026-06-300001583771us-gaap:TreasuryStockCommonMember2026-04-012026-06-300001583771us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-300001583771us-gaap:RetainedEarningsMember2026-04-012026-06-3000015837712026-04-012026-06-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2026-07-012026-09-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2026-07-012026-09-300001583771us-gaap:CommonStockMember2026-07-012026-09-300001583771us-gaap:TreasuryStockCommonMember2026-07-012026-09-300001583771us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-07-012026-09-300001583771us-gaap:RetainedEarningsMember2026-07-012026-09-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2025-01-012025-03-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2025-01-012025-03-310001583771us-gaap:CommonStockMember2025-01-012025-03-310001583771us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001583771us-gaap:RetainedEarningsMember2025-01-012025-03-3100015837712025-01-012025-03-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2025-04-012025-06-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2025-04-012025-06-300001583771us-gaap:CommonStockMember2025-04-012025-06-300001583771us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001583771us-gaap:RetainedEarningsMember2025-04-012025-06-3000015837712025-04-012025-06-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2025-07-012025-09-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2025-07-012025-09-300001583771us-gaap:CommonStockMember2025-07-012025-09-300001583771us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300001583771us-gaap:RetainedEarningsMember2025-07-012025-09-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2026-09-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2026-09-300001583771us-gaap:CommonStockMember2026-09-300001583771us-gaap:TreasuryStockCommonMember2026-09-300001583771us-gaap:AdditionalPaidInCapitalMember2026-09-300001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-09-300001583771us-gaap:RetainedEarningsMember2026-09-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2025-09-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesCPreferredStockMember2025-09-300001583771us-gaap:CommonStockMember2025-09-300001583771us-gaap:AdditionalPaidInCapitalMember2025-09-300001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300001583771us-gaap:RetainedEarningsMember2025-09-3000015837712025-09-300001583771HEPA:CirnaDiagnosticsLLCMember2026-01-012026-09-300001583771HEPA:CirnaDiagnosticsLLCMembersrt:MaximumMember2026-01-012026-09-300001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMember2026-04-212026-04-210001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMember2026-04-210001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMemberus-gaap:CommonStockMember2026-07-312026-07-310001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMember2026-07-310001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMemberus-gaap:WarrantMember2026-07-312026-07-310001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMember2026-07-312026-07-310001583771HEPA:SecuritiesPurchaseAgreementsMember2026-07-310001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMemberus-gaap:CommonStockMember2026-08-262026-08-260001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMemberus-gaap:CommonStockMember2026-09-292026-09-290001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMember2026-08-260001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMember2026-09-290001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMemberus-gaap:WarrantMember2026-08-262026-08-260001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMemberus-gaap:WarrantMember2026-09-292026-09-290001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMember2026-08-262026-08-260001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMember2026-09-292026-09-290001583771HEPA:SecuritiesPurchaseAgreementsMember2026-08-260001583771HEPA:SecuritiesPurchaseAgreementsMember2026-09-290001583771us-gaap:PrivatePlacementMemberHEPA:SecuritiesPurchaseAgreementsMember2026-04-210001583771us-gaap:TreasuryStockCommonMember2026-07-222026-07-220001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMemberus-gaap:WarrantMember2026-08-260001583771HEPA:SecuritiesPurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMemberus-gaap:WarrantMember2026-09-290001583771us-gaap:WarrantMemberus-gaap:SubsequentEventMember2026-10-010001583771us-gaap:WarrantMemberHEPA:AugustTwoThousandTwentySixOfferingWarrantsMemberus-gaap:SubsequentEventMember2026-10-010001583771HEPA:JulyTwoThousandTwentySixOfferingWarrantsMemberus-gaap:SubsequentEventMember2026-10-010001583771HEPA:JulyTwoThousandTwentySixOfferingWarrantsMemberus-gaap:SubsequentEventMember2026-10-012026-10-010001583771us-gaap:AdditionalPaidInCapitalMember2026-01-012026-09-300001583771us-gaap:SeriesAPreferredStockMember2026-07-012026-09-300001583771us-gaap:SeriesAPreferredStockMember2026-01-012026-09-300001583771us-gaap:SeriesAPreferredStockMember2025-07-012025-09-300001583771us-gaap:SeriesAPreferredStockMember2025-01-012025-09-3000015837712025-01-232025-01-230001583771HEPA:SeriesACommonWarrantMember2025-01-230001583771HEPA:SeriesBCommonWarrantMember2025-01-230001583771HEPA:SeriesAWarrantMember2026-09-300001583771HEPA:SeriesBWarrantMember2026-09-300001583771HEPA:SeriesBWarrantMember2025-01-012025-12-310001583771HEPA:SeriesAWarrantMember2026-01-012026-09-300001583771HEPA:SeriesAAndBCommonWarrantMember2025-01-230001583771HEPA:PrefundedWarrantMember2025-01-2300015837712025-01-230001583771srt:MinimumMemberHEPA:SeriesBWarrantMember2025-01-232025-01-230001583771HEPA:SeriesBWarrantMember2025-01-230001583771us-gaap:CommonStockMember2025-01-230001583771HEPA:SeriesBWarrantMember2025-04-042025-04-040001583771HEPA:SeriesAWarrantMember2025-04-040001583771HEPA:SeriesAWarrantMember2025-04-042025-04-040001583771HEPA:JulyTwoThousandTwentySixOfferingWarrantsMemberus-gaap:CommonStockMember2026-09-300001583771HEPA:SeptemberTwoThousandTwentySixOfferingWarrantsMemberus-gaap:CommonStockMember2026-09-300001583771us-gaap:WarrantMember2026-09-300001583771us-gaap:WarrantMemberHEPA:JulyTwoThousandTwentySixOfferingWarrantsMember2026-09-300001583771us-gaap:WarrantMemberHEPA:AugustTwoThousandTwentySixOfferingWarrantsMember2026-09-300001583771HEPA:AugustTwoThousandTwentySixOfferingWarrantsMember2026-09-300001583771HEPA:JulyTwoThousandTwentySixOfferingWarrantMember2026-09-300001583771us-gaap:FairValueInputsLevel2Memberus-gaap:MeasurementInputSharePriceMember2026-09-300001583771us-gaap:FairValueInputsLevel2Memberus-gaap:MeasurementInputExpectedTermMember2026-09-300001583771us-gaap:FairValueInputsLevel2Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-09-300001583771us-gaap:FairValueInputsLevel2Memberus-gaap:MeasurementInputPriceVolatilityMember2026-09-300001583771us-gaap:CommonStockMember2026-10-010001583771HEPA:GravitasWarrantsMemberus-gaap:CommonStockMember2026-09-300001583771us-gaap:MeasurementInputSharePriceMember2026-09-300001583771us-gaap:MeasurementInputSharePriceMember2025-12-310001583771us-gaap:MeasurementInputExpectedTermMember2026-09-300001583771us-gaap:MeasurementInputExpectedTermMember2025-12-310001583771us-gaap:MeasurementInputRiskFreeInterestRateMember2026-09-300001583771us-gaap:MeasurementInputRiskFreeInterestRateMember2025-12-310001583771us-gaap:MeasurementInputPriceVolatilityMember2026-09-300001583771us-gaap:MeasurementInputPriceVolatilityMember2025-12-310001583771us-gaap:MeasurementInputExpectedDividendRateMember2026-09-300001583771us-gaap:MeasurementInputExpectedDividendRateMember2025-12-310001583771HEPA:TwoThousandTwentySixPrivatePlacementWarrantsMemberus-gaap:MeasurementInputSharePriceMember2026-09-300001583771HEPA:TwoThousandTwentySixPrivatePlacementWarrantsMemberus-gaap:MeasurementInputSharePriceMember2025-12-310001583771HEPA:TwoThousandTwentySixPrivatePlacementWarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2026-09-300001583771HEPA:TwoThousandTwentySixPrivatePlacementWarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2026-09-300001583771HEPA:TwoThousandTwentySixPrivatePlacementWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2025-12-310001583771us-gaap:MeasurementInputRiskFreeInterestRateMemberHEPA:TwoThousandTwentySixPrivatePlacementWarrantsMembersrt:MinimumMember2026-09-300001583771us-gaap:MeasurementInputRiskFreeInterestRateMemberHEPA:TwoThousandTwentySixPrivatePlacementWarrantsMembersrt:MaximumMember2026-09-300001583771us-gaap:MeasurementInputRiskFreeInterestRateMemberHEPA:TwoThousandTwentySixPrivatePlacementWarrantsMember2025-12-310001583771us-gaap:MeasurementInputPriceVolatilityMemberHEPA:TwoThousandTwentySixPrivatePlacementWarrantsMembersrt:MinimumMember2026-09-300001583771us-gaap:MeasurementInputPriceVolatilityMemberHEPA:TwoThousandTwentySixPrivatePlacementWarrantsMembersrt:MaximumMember2026-09-300001583771us-gaap:MeasurementInputPriceVolatilityMemberHEPA:TwoThousandTwentySixPrivatePlacementWarrantsMember2025-12-310001583771us-gaap:MeasurementInputExpectedDividendRateMemberHEPA:TwoThousandTwentySixPrivatePlacementWarrantsMember2026-09-300001583771us-gaap:MeasurementInputExpectedDividendRateMemberHEPA:TwoThousandTwentySixPrivatePlacementWarrantsMember2025-12-310001583771HEPA:SeriesAWarrantsMember2026-09-300001583771HEPA:SeriesAWarrantsMember2025-12-310001583771HEPA:SeriesBOneWarrantsMember2026-09-300001583771HEPA:SeriesBOneWarrantsMember2025-12-310001583771HEPA:TwoThousandAndTwentyFiveSeriesAWarrantsMember2026-09-300001583771HEPA:TwoThousandAndTwentyFiveSeriesAWarrantsMember2025-12-310001583771HEPA:JulyTwoThousandTwentySixOfferingWarrantsMember2026-09-300001583771HEPA:JulyTwoThousandTwentySixOfferingWarrantsMember2025-12-310001583771HEPA:AugustTwoThousandTwentySixOfferingWarrantsMember2025-12-310001583771us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2025-12-310001583771us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2026-01-012026-09-300001583771us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2026-09-300001583771HEPA:DirectorsAndOfficersLiabilityAgreementMember2025-03-150001583771HEPA:DirectorsAndOfficersLiabilityAgreementMember2025-03-152025-03-150001583771HEPA:SecuredConvertibleNoteMember2026-09-030001583771HEPA:ConvertibleNotePurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMemberus-gaap:WarrantMember2026-09-032026-09-030001583771HEPA:ConvertibleNotePurchaseAgreementsMemberHEPA:InvestorsMemberus-gaap:PrivatePlacementMember2026-09-030001583771HEPA:SecuredConvertibleNoteMember2026-01-012026-09-300001583771us-gaap:ConvertibleDebtMember2026-01-012026-09-300001583771HEPA:ConvertibleNoteWarrantsMember2026-01-012026-09-300001583771HEPA:SecuredConvertibleNoteMember2026-09-300001583771us-gaap:FairValueMeasurementsRecurringMember2026-09-300001583771us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-09-300001583771us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-09-300001583771us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2026-09-300001583771us-gaap:FairValueMeasurementsRecurringMember2025-12-310001583771us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001583771us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001583771us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001583771HEPA:TwoThousandThirteenEquityIncentivePlanMember2013-06-032013-06-030001583771HEPA:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMembersrt:MaximumMember2023-04-300001583771HEPA:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember2026-06-170001583771HEPA:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember2026-08-270001583771HEPA:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember2026-09-300001583771us-gaap:EmployeeStockOptionMember2026-07-012026-09-300001583771us-gaap:EmployeeStockOptionMember2026-01-012026-09-300001583771us-gaap:EmployeeStockOptionMember2025-07-012025-09-300001583771us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001583771us-gaap:EmployeeStockOptionMember2026-09-300001583771us-gaap:GeneralAndAdministrativeExpense2026-07-012026-09-300001583771us-gaap:GeneralAndAdministrativeExpense2025-07-012025-09-300001583771us-gaap:GeneralAndAdministrativeExpense2026-01-012026-09-300001583771us-gaap:GeneralAndAdministrativeExpense2025-01-012025-09-300001583771us-gaap:ResearchAndDevelopmentExpense2026-07-012026-09-300001583771us-gaap:ResearchAndDevelopmentExpense2025-07-012025-09-300001583771us-gaap:ResearchAndDevelopmentExpense2026-01-012026-09-300001583771us-gaap:ResearchAndDevelopmentExpense2025-01-012025-09-300001583771us-gaap:ShareBasedCompensation2026-07-012026-09-300001583771us-gaap:ShareBasedCompensation2025-07-012025-09-300001583771us-gaap:ShareBasedCompensation2026-01-012026-09-300001583771us-gaap:ShareBasedCompensation2025-01-012025-09-300001583771us-gaap:EmployeeStockOptionMember2025-12-310001583771us-gaap:EmployeeStockOptionMember2025-01-012025-12-310001583771us-gaap:SeriesAPreferredStockMember2026-01-012026-09-300001583771us-gaap:SeriesAPreferredStockMember2025-01-012025-09-300001583771us-gaap:SeriesCPreferredStockMember2026-01-012026-09-300001583771us-gaap:SeriesCPreferredStockMember2025-01-012025-09-300001583771us-gaap:EmployeeStockOptionMember2026-01-012026-09-300001583771us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001583771HEPA:WarrantsLiabilityMember2026-01-012026-09-300001583771HEPA:WarrantsLiabilityMember2025-01-012025-09-300001583771us-gaap:WarrantMember2026-01-012026-09-300001583771us-gaap:WarrantMember2025-01-012025-09-300001583771HEPA:ConvertibleNoteMember2026-01-012026-09-300001583771HEPA:ConvertibleNoteMember2025-01-012025-09-300001583771HEPA:LoPrioreEmploymentAgreementMember2026-01-012026-09-300001583771HEPA:StetzEmploymentAgreementMember2026-01-012026-09-300001583771HEPA:AppajosyulaEmploymentAgreementMember2026-01-012026-09-300001583771HEPA:SeparationAgreementMember2026-04-132026-04-130001583771HEPA:SeparationAgreementMember2026-09-3000015837712026-09-032026-09-0300015837712026-09-030001583771HEPA:ConvertibleNoteMember2026-09-030001583771HEPA:ConvertibleNoteAndWarrantMember2026-09-030001583771HEPA:ConvertibleNoteAndWarrantMember2026-09-300001583771HEPA:GravitasLifeSciencesLLCMember2026-09-080001583771HEPA:GravitasLifeSciencesLLCMember2026-09-082026-09-080001583771HEPA:PresidentStreetGlobalLLCMember2026-09-012026-09-300001583771HEPA:PresidentStreetGlobalLLCMember2026-01-012026-09-300001583771us-gaap:SubsequentEventMember2026-10-010001583771us-gaap:SubsequentEventMembersrt:MinimumMember2026-10-010001583771us-gaap:SubsequentEventMembersrt:MinimumMemberus-gaap:WarrantMember2026-10-010001583771us-gaap:CommonStockMemberHEPA:MembershipInterestPurchaseAgreementMemberus-gaap:SubsequentEventMember2026-10-060001583771us-gaap:CommonStockMemberHEPA:MembershipInterestPurchaseAgreementMemberus-gaap:SubsequentEventMember2026-10-062026-10-0600015837712026-10-062026-10-060001583771us-gaap:CommonStockMemberHEPA:MembershipInterestPurchaseAgreementMemberHEPA:CantonStrategicHoldingsMemberus-gaap:SubsequentEventMember2026-10-060001583771us-gaap:CommonStockMemberHEPA:MembershipInterestPurchaseAgreementMemberHEPA:GravitasLifeSciencesLLCMemberus-gaap:SubsequentEventMember2026-10-06iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM10-Q

 

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended September 30, 2026

 

Or

 

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission File Number 001-36856

 

 

HEPION PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 46-2783806
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)

 

22 West Street

Red Bank, NJ 07701

(Address of Principal Executive Offices)

 

(732)902-4000

Registrant’s telephone number, including area code

 

34 Shrewsbury Ave., Suite 1D

Red Bank, NJ 07701

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share HEPA OTC QB

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

 

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares of the registrant’s Common Stock outstanding as of November 8, 2026 was 125,074,297.

 

 

 

 
 

 

HEPION PHARMACEUTICALS, INC.

FORM 10-Q

TABLE OF CONTENTS

 

 Page
PART I—FINANCIAL INFORMATION 
Item 1.Condensed Consolidated Financial Statements (unaudited):2
 Condensed Consolidated Balance Sheets2
 Condensed Consolidated Statements of Operations3
 Condensed Consolidated Statements of Comprehensive Loss4
 Condensed Consolidated Statements of Changes in Stockholders’ Equity5
 Condensed Consolidated Statements of Cash Flows6
 Notes to Condensed Consolidated Financial Statements7
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17
Item 3.Quantitative and Qualitative Disclosures About Market Risk23
Item 4.Controls and Procedures23
  
PART II—OTHER INFORMATION 
  
Item 1A.Risk Factors24
Item 6.Exhibits24
SIGNATURES25

 

 
 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q for Hepion Pharmaceuticals, Inc. may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, those discussed under Item 1A. Risk Factors and elsewhere in the audited consolidated financial statements as of and for the year ended December 31, 2025 contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2026, as well as under Item 1A . Risk Factors within this Form 10-Q. These factors include the uncertainties associated with:

 

●our ability to raise substantial additional capital to continue as a going concern and fund our planned operations in the near term;
  
●estimates regarding our expenses, use of cash, timing of future cash needs and anticipated capital requirements;
  
●success in retaining, or changes required in, our officers, key employees or directors;
  
●our public securities’ potential liquidity and trading;
  
●our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations or warnings in the label of any of our product candidates, if approved;
  
●our plans to pursue research and development of other future product candidates;
  
●the potential advantages of our product candidates and those being developed;
  
●the rate and degree of market acceptance and clinical utility of our product candidates;
  
●the success of our collaborations and partnerships with third parties;
  
●our estimates regarding the potential market opportunity for our product candidates;
  
●our sales, marketing and distribution capabilities and strategy;
  
●our ability to establish and maintain arrangements for manufacture of our product candidates;
  
●our ability to compete with companies currently marketing or engaged in the development of treatments for indications that our product candidates are designed to target; and
  
●our intellectual property position, including the strength and enforceability of our intellectual property rights.

 

We do not assume any obligation to update forward-looking statements as circumstances change and thus you should not unduly rely on these statements.

 

1

 

PART I—FINANCIAL INFORMATION

 

Item 1. Condensed Consolidated Financial Statements

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

  September 30,
2026
  December 31,
2025
 
Assets        
Current assets:        
Cash $4,255,346  $1,828,062 
Prepaid expenses  187,445   1,241,890 
Related party receivable  500,000   — 
Total current assets  4,942,791   3,069,952 
Right-of-use asset  61,003   — 
Other assets  2,000   — 
Total assets $5,005,794  $3,069,952 
         
Liabilities and Stockholders’ Equity        
Current liabilities:        
Accounts payable $160,963  $167,810 
Accrued expenses  635,155   77,507 

Accrued interest

  2,959   — 
Related party note payable, current  296,623   54,066 

Operating lease liability, current

  18,953   — 
Total current liabilities  1,114,653   299,383 
         

Operating lease liability, non-current

  42,050   — 
Derivative financial instruments—warrants  7,865,796   103,022 
Total liabilities  9,022,499   402,405 
Commitments and contingencies (see Note 10)  -   - 
Stockholders’ equity:        
Series A convertible preferred stock, stated value $10 per share, 85,581 shares issued and outstanding at September 30, 2026 and December 31, 2025.  855,808   855,808 
Series C convertible preferred stock, stated value $1,000 per share, 1,688 shares issued and outstanding at September 30, 2026 and December 31, 2025.  839,320   839,320 
Convertible preferred stock  839,320   839,320 
         
         
Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 100,420,317 and 11,620,317 shares issued and 100,074,297 and 11,620,317 shares outstanding at September 30, 2026 and December 31, 2025, respectively.  10,042   1,162 
Treasury stock, at cost; 346,020 and 0 shares at September 30, 2026 and December 31, 2025, respectively  (21,799)  — 
Additional paid-in capital  247,031,183   247,060,568 
Accumulated other comprehensive income.  8,345   8,345 
Accumulated deficit  (252,739,604)  (246,097,656)
Total stockholders’ equity (deficit)  (4,016,705)  2,667,547 
Total liabilities and stockholders’ equity $5,005,794  $3,069,952 

 

The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).

 

2

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited)

 

  2026  2025  2026  2025 
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
 
  2026  2025  2026  2025 
Revenues $—  $—  $—  $— 
Cost and expenses:                
Research and development  134,654   —   255,572   445,512 
General and administrative  1,415,892   527,902   3,304,974   2,705,750 
Asset impairment loss  —   —   —   402,746 
Total operating expenses  1,550,546   527,902   3,560,546   3,554,008 
Loss from operations  (1,550,546)  (527,902)  (3,560,546)  (3,554,008)
                 
Other income (expense):                
Interest income (expense)  (3,494)  8,116   620   (11,829)
Other income (expense), net  6,255   —   6,255   — 
Change in fair value of derivative financial instruments-warrants  (3,035,135)  47,280   (3,088,277)  (4,055,128)
Net loss $(4,582,920) $(472,506) $(6,641,948) $(7,620,965)
                 
Weighted-average common shares outstanding:                
Basic and diluted  71,137,656   11,620,317   36,100,383   8,653,428 
                 
Net loss per common share: (see Note 9)                
Basic and diluted $(0.06) $(0.04) $(0.18) $(0.88)

 

The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).

 

3

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

 

  2026  2025  2026  2025 
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  2026  2025  2026  2025 
Net loss $(4,582,920) $(472,506) $(6,641,948) $(7,620,965)
Other comprehensive income (loss):                
Foreign currency translation  —   —   —   — 
Total other comprehensive income (loss)  —   —   —   — 
Comprehensive loss $(4,582,920) $(472,506) $(6,641,948) $(7,620,965)

 

The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).

 

4

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

 

  Shares  Amount  Shares  Amount  Shares  Amount  stock  Capital  Income  Deficit  Equity 
  Preferred Stock  Preferred Stock        Additional  Accumulated other     Total 
  Series A  Series C  Common Stock  Treasury  Paid in  Comprehensive  Accumulated  Stockholders’ 
  Shares  Amount  Shares  Amount  Shares  Amount  stock  Capital  Income  Deficit  Equity 
Balance at December 31, 2025  85,581  $855,808   1,688  $839,320   11,620,317  $1,162       —  $247,060,568  $8,345  $(246,097,656) $2,667,547 
                                             
Net loss  —   —   —   —   —   —   -   —   —   (810,791)  (810,791)
Balance at March 31, 2026  85,581  $855,808   1,688  $839,320   11,620,317   1,162   -  $247,060,568  $8,345  $(246,908,447) $1,856,756 
                                             
Net loss  —   —   —   —   —   —   -   —   —   (1,248,237)  (1,248,237)
Issuance of common stock, net  —   —   —   —   17,500,000   1,750   -   668,250   —   —   670,000 
Balance at June 30, 2026  85,581  $855,808   1,688  $839,320   29,120,317   2,912   -  $247,728,818  $8,345  $(248,156,684) $1,278,519 
Net loss  —   —   —   —   —   —   —   —   —   (4,582,920)  (4,582,920)
Stock-based compensation expense  —   —   —   —   —   —   -   245,637   —   —   245,637 
Issuance of common stock and warrants, net of warrant liabilities  —   —   —   —   71,300,000   7,130   -   1,152,718   —   —   1,159,848 
Reclassification of July and August 2026 Offering warrants to liabilities  —   —   —   —   —   —   —   (2,300,181)  —   —   (2,300,181)

Warrants issued in connection with convertible note

  —   —   —   —   —   —   —   204,191   —   —   204,191 
Common stock returned and held in treasury (346,020 shares)  —   —   —   —   —   —   

(21,799

)  —   —   —   (21,799)
Balance at September 30, 2026  85,581  $855,808   1,688  $839,320   100,420,317   10,042   

(21,799

) $247,031,183  $8,345  $(252,739,604) $(4,016,705)

 

  Shares  Amount  Shares  Amount  Shares  Amount  Capital  Income  Deficit  Equity 
  Preferred Stock  Preferred Stock     Additional  Accumulated other     Total 
  Series A  Series C  Common Stock  Paid in  Comprehensive  Accumulated  Stockholders’ 
  Shares  Amount  Shares  Amount  Shares  Amount  Capital  Income  Deficit  Equity 
Balance at December 31, 2024  85,581  $855,808   1,688  $839,320   139,168  $14  $234,252,981  $8,345  $(237,819,806) $(1,863,338)
                                         
Net loss  —   —   —   —   —   —   —   —   (6,105,887)  (6,105,887)
Stock-based compensation expense  —   —   —   —   —   —   20,783   —   —   20,783 
Issuance of restricted stock units  —   —   —   —   1,000   —   —   —   —   — 
Issuance of common stock and pre-funded warrants, net  —   —   —   —   553,846   55   2,086,537   —   —   2,086,592 
Issuance of common stock in connection with stock split  —   —   —   —   60,860   6   (6)  —   —   — 
Conversion of 2025 Series B warrants into common stock  —   —   —   —   8,834,034   884   9,757,029   —   —   9,757,913 
Balance at March 31, 2025  85,581  $855,808   1,688  $839,320   9,588,908   959  $246,117,324  $8,345  $(243,925,693) $3,896,063 
                                         
Net loss  —   —   —   —   —   —   —   —   (1,042,572)  (1,042,572)
Conversion of 2025 Series B warrants into common stock  —   —   —   —   1,339,368   134   672,684   —   —   672,818 
Issuance of common stock in connection with license agreement  —   —   —   —   692,041   69   270,560   —   —   270,629 
Balance at June 30, 2025  85,581  $855,808   1,688  $839,320   11,620,317   1,162  $247,060,568  $8,345  $(244,968,265) $3,796,938 
Balance  85,581  $855,808   1,688  $839,320   11,620,317   1,162  $247,060,568  $8,345  $(244,968,265) $3,796,938 
Net loss  —   —   —   —   —   —   —   —   (472,506)  (472,506)
Balance at September 30, 2025  85,581  $855,808   1,688  $839,320   11,620,317   1,162  $247,060,568  $8,345  $(245,440,771) $3,324,432 
Balance  85,581  $855,808   1,688  $839,320   11,620,317   1,162  $247,060,568  $8,345  $(245,440,771) $3,324,432 

 

The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).

 

5

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

  2026  2025 
  Nine Months Ended
September 30,
 
  2026  2025 
Cash flows from operating activities:        
Net loss $(6,641,948) $(7,620,965)
Adjustments to reconcile net loss to net cash used in operating activities:        
Stock-based compensation  245,637   20,783 
Asset impairment loss  —   402,746 
Change in fair value of derivative financial instruments—warrants  3,088,277   4,055,133 
Offering costs allocated to warrant liabilities  15,544   — 
Gain on return of common stock  (21,799)  — 
Amortization of debt discount and issuance costs  10,814   — 
Changes in operating assets and liabilities:        
Accounts payable and accrued expenses  553,760   (110,786)
Prepaid expenses and other assets  1,052,445   314,344 
Net cash used in operating activities  (1,697,270)  (2,938,745)
         
Cash flows from investing activities:        
Investment in license agreement  —   (132,117)
Related party loan receivable  (500,000)  — 
Net cash used in investing activities  (500,000)  (132,117)
Cash flows from financing activities:        
Proceeds from the issuance of common stock and warrants, net  4,265,000   9,000,000 
Equity issuance costs  (76,380)  (802,597)
Proceeds from note payable, net  490,000   — 
Payments on notes payable  (54,066)  (3,211,871)
Net cash provided by financing activities  4,624,554   4,985,532 
Net increase (decrease) in cash  2,427,284   1,914,670 
Cash at beginning of period  1,828,062   406,408 
Cash at end of period $4,255,346  $2,321,078 
         
Supplementary disclosure of non-cash financing activities:        
Issuance of Note Payable for payment of prepaid expense  —   526,178 
Cashless Exercise of 2025 Series B Warrants $—  $10,430,732 
Issuance of common stock in connection with license agreement $—  $270,629 
Common stock returned and held in treasury  21,799   — 

Warrants issued in connection with convertible note

  204,191   — 

Right-of-use asset obtained in exchange for operating lease liability

  60,499   — 
Initial fair value of warrants liabilities issued in private placements  2,374,316   — 
Reclassification of warrants from equity to liabilities  2,300,181   — 

 

The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).

 

6

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

1.Business Overview

 

Hepion Pharmaceuticals, Inc. (we, our, or us) is a medical diagnostic company headquartered in Red Bank, New Jersey, that was previously focused on the development of drug therapy for treatment of chronic liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), was being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease.

 

On February 25, 2026, we entered into an intellectual property license agreement with Cirna Diagnostics, LLC (“Cirna”) pursuant to which we licensed certain liver disease diagnostic assets from Cirna. We paid an upfront payment of $70,000 during the nine months ended September 30, 2026 and will pay up to $2,350,000 in milestone payments, up to $4,500,000 in sales milestone payments and a royalty payment on net sales in the low single digits. We accounted for this transaction as an asset acquisition. The total consideration of $70,000 was allocated to purchased in-process research and development, and it was expensed upon the completion of the transaction. We did not recognize any contingent consideration (milestone payments) given the low probability of meeting those targets. Royalties will be recognized when earned.

 

2.Basis of Presentation

 

Basis of Presentation

 

These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2025, was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2025, contained in our Annual Report on Form 10-K filed with the SEC on March 12, 2026.

 

Principles of Consolidation

 

The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada (all subsidiaries are currently dormant). All intercompany balances and transactions have been eliminated in consolidation.

 

Going Concern

 

As of September 30, 2026, we had $4.3 million in cash, an accumulated deficit of $252.7 million, a stockholders’ deficit of $4.0 million, and working capital of $3.8 million. For the nine months ended September 30, 2026, cash used in operating activities was $1.7 million. We have not generated revenue to date and have incurred substantial losses and negative cash flows from operations since our inception. We have historically funded our operations through the issuance of convertible preferred stock, warrants, the issuance and sale of shares of our common stock, including shares sold through at-the market offerings. Our ability to continue operations after our current cash resources are exhausted depends on future events outside of our control, including our ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given. If adequate additional funds are not available when required, management may need to curtail planned operations to conserve cash until sufficient additional capital can be raised. There can be no assurances that such a plan would be successful.

 

7

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

These condensed consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to us. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business. If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) seek collaborators for our product candidates on terms that are less favorable than might otherwise be available; or (ii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.

 

On April 21, 2026, we entered into securities purchase agreements (the “Agreements”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering (the “April 2026 Offering”), an aggregate of 17,500,000 shares of common stock, par value $0.0001 per share at an offering price of $0.04 per share for gross proceeds of $700,000. The Offering closed on April 21, 2026.

 

On July 31, 2026, we entered into securities purchase agreements with certain accredited investors pursuant to which the Company agreed to sell and issue 61,100,000 shares of common stock, par value $0.0001 per share, and warrants to purchase 61,100,000 shares of common stock, in a private placement offering (the “July 2026 Offering”), at an offering price of $0.05 for gross proceeds of approximately $3.1 million. The warrants are exercisable at an exercise price of $0.06 per share for five years from the date of issuance. The July 2026 Offering closed on August 3, 2026.

 

In addition, on August 26, 2026 (the “August 2026 Offering”) and September 29, 2026 (the “September 2026 Offering”), we entered into securities purchase agreements with certain accredited investors pursuant to which the Company agreed to sell and issue8,000,000 and 2,200,000 shares of common stock, respectively, par value $0.0001 per share, and warrants to purchase 10,200,000 shares of common stock, in private placement offerings at an offering price of $0.05 for aggregate gross proceeds of approximately $0.5 million. The warrants are exercisable at an exercise price of $0.06 per share for five years from the date of issuance.

 

3.Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.

 

Our significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2025, included in our Annual Report on Form 10-K. Since the date of such consolidated financial statements, there have been no changes to our significant accounting policies.

 

Recent Accounting Pronouncements

 

There are no recent accounting pronouncements that will have a material effect on our condensed consolidated financial statements for the three and nine months ended September 30, 2026.

 

8

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

4.Stockholders’ Equity

 

On April 21, 2026, the Company entered into securities purchase agreements (the “Agreements”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering (the “Offering”), an aggregate of 17,500,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) at an offering price of $0.04 per share for gross proceeds of $700,000.

 

On July 22, 2026, the Company and New Day Diagnostics LLC (“New Day”) entered into a termination and release agreement (the “Termination Agreement”) terminating the Intellectual Property License Agreement dated May 9, 2025, Amendment I to the Intellectual Property License Agreement dated October 16, 2025, and the Commercial Consulting Services Statement of Work dated June 23, 2025. Pursuant to the Termination Agreement, New Day returned 346,020 shares of Common Stock to the Company, recorded as treasury stock in the accompanying consolidated balance sheet.

 

On July 31, 2026, we closed the July 2026 Offering, pursuant to which the Company agreed to sell and issue 61,100,000 shares of common stock, par value $0.0001 per share, and warrants to purchase 61,100,000 shares of common stock, in a private placement offering, at an offering price of $0.05 for gross proceeds of approximately $3.1 million. The warrants are exercisable at an exercise price of $0.06 per share for five years from the date of issuance. The July 2026 Offering closed on August 3, 2026.

 

In addition, during third quarter of 2026, we closed the August 2026 Offering and the September 2026 Offering, pursuant to which the Company agreed to sell an aggregate of 10,200,000 shares of common stock, par value $0.0001 per share, and warrants to purchase 10,200,000 shares of common stock, at an offering price of $0.05 per share for gross proceeds of approximately $0.5 million. The warrants are exercisable at an exercise price of $0.06 per share for five years from the date of issuance.

 

Because the Company did not have sufficient authorized and unissued shares of common stock to settle all of the warrants issued in the July 2026, August 2026 and September 2026 Offerings and the shares issuable on conversion of the Convertible Note (see Note 5) until its authorized common stock was increased on October 1, 2026, the Company applied its sequencing policy, under which instruments are reclassified to liabilities beginning with the earliest-issued instrument. Under this policy, 68,698,111 warrants were classified as liabilities and measured at fair value (see Note 4). The remaining 401,889 August 2026 Offering warrants and all of the warrants issued in the September 2026 Offering were classified in stockholders’ equity. At issuance, $2,374,316 of the $3,055,000 gross proceeds of the July 2026 Offering was allocated to the warrant liability at fair value and the remaining $680,684 to stockholders’ equity. The warrants reclassified after issuance were reclassified from stockholders’ equity to liabilities at their fair value on the reclassification dates of $2,300,181, with the offset to additional paid-in capital. Offering costs of $15,544 allocated to the liability-classified warrants were expensed within other income (expense), net.

 

Series A Convertible Preferred Stock

 

Each share of the Series A is convertible at the option of the holder into the number of shares of common stock determined by dividing the stated value of such share by the conversion price that is subject to adjustment. As of September 30, 2026, there were 85,581 shares outstanding. During the three and nine months ended September 30, 2026 and 2025, no shares of the Series A were converted. If we sell common stock or equivalents at an effective price per share that is lower than the conversion price, the conversion price may be reduced to the lower conversion price. The Series A will be automatically convertible into common stock in the event of a fundamental transaction as defined in the offering agreements.

 

Series C Convertible Preferred Stock Issuance

 

As of September 30, 2026, there were 1,688 shares outstanding. There were no conversions for the three and nine months ended September 30, 2026 and 2025. Each share of Series C is convertible into common stock at any time at the option of the holder thereof at the conversion price then in effect. The conversion price for the Series C is determined by dividing the stated value of $1,000 per share by $0.0092per share (subject to adjustments upon the occurrence of certain dilutive events).

 

Common Stock and Warrant Offering

 

The fair value of these liability classified warrants was estimated using the Black-Scholes option pricing model. This method of valuation involves using inputs such as the fair value of our common stock, historical volatility, the contractual term of the warrants, risk-free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 2 measurement (see Note 6). The following assumptions were used to measure the Series A and Series B-1 Warrants as of September 30, 2026 and December 31, 2025.

 Schedule of Assumptions Used to Calculate Fair Value of Liability

  September 30, 2026  December 31, 2025 
Stock price $0.11  $0.06 
Expected warrant term (years)  2.4 years   3.1 years 
Risk-free interest rate  4.94%  3.64%
Expected volatility  224.90%  171.05%
Dividend yield  —   — 

 

9

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

The exercise price, amount of warrants outstanding and fair value for all warrants as of September 30, 2026 and December 31, 2025 are as follows:

Schedule of Warrants Outstanding and Fair Value for Warrants 

 

  September 30, 2026  December 31, 2025 
  Exercise Price  Warrants Outstanding  Fair Value  Exercise Price  Warrants Outstanding  Fair Value 
Series A Warrants $95.50   19,608   —  $95.50   19,608   — 
Series B-1 Warrants $95.50   14,706   —  $95.50   14,706   — 
2025 Series A Warrants $3.22   3,443,461  $290,592  $3.22   3,443,461  $103,022 
July 2026 Offering Warrants $0.06   61,100,000  $6,737,244   —   —   — 
August 2026 Offering Warrants (liability-classified portion) $0.06   7,598,111  $837,960   —   —   — 
Total      72,175,886  $7,865,796       3,477,775  $103,022 

 

On January 23, 2025, we consummated a “best efforts” public offering of 553,846shares of common stock (or pre-funded warrants in lieu thereof) with each share of common stock (or pre-funded warrant) accompanied by (i) a series A common warrant to purchase one (1) common share at an exercise price of $20.00per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $20.00per share. The exercise periods for the Series A and B warrants are five years and two and ½ years. The Series B warrants have an alternate cashless exercise of one warrant for three common shares and there is no exercise price associated with a cashless exercise (including no exercise price incorporated into the calculation of shares issuable under the cashless exercise).

 

The Company accounted for Series A and Series B warrants as liability awards and the Pre-Funded Warrant as a permanent equity, using an allocation of 75% for the liability and 25% for the equity components. A total of $2.3 million was recorded to permanent equity for the common stock and pre-funded warrants. The Series A and Series B Warrants were recorded at fair value on the date of issuance, and remeasured at fair value at the balance sheet date, with changes in fair value recorded to earnings. The Series A and Series B Warrant liabilities were assessed to be $1.3 million and $5.4 million, respectively, on the day of the transaction. As of December 31, 2025, a total of 10,173,402Series B warrants were exercised and converted into common shares. As of September 30, 2026, none of the Series A warrants have been exercised, and the fair value of the Series A warrant liability was approximately $0.3 million. The total number of unexercised Series A warrants as of September 30, 2026 was 3,443,461. All of the pre-funded warrants were exercised as of March 31, 2025.

 

As part of the transaction, the Company incurred equity issuance costs of $0.8 million related to advisory and legal fees directly attributable to the issuance of the common stock from the Series A and Series B Warrant Agreement, which were allocated at $0.2 million and $0.6 million against additional paid-in-capital and warrant liability (expensed to change in fair value), respectively.

 

The combined offering price of each share of common stock together with the accompanying Series A and Series B common warrants is $16.250, and the combined offering price of each pre-funded warrant, all of which were exercised as of April 2, 2025, together with the accompanying series A and series B common warrants is $16.245. The gross proceeds of the public offering were approximately $9.0 million before deducting placement agent fees and offering expenses and were used to repay certain indebtedness ($2.9M note payable) and expected to be used for general corporate purposes, including working capital, operating expenses and capital expenditures.

 

The Series B warrants contained certain volume weighted average price provisions that reset the exercise price to a minimum floor price of $3.22 and also resets the number of warrants to 3,406,390 which are exercisable into 10,173,402 common shares.

 

As of April 4, 2025 all of the Series B warrants were exercised into common shares at a weighted average reset price of $3.27. Since the Series B warrants were exercised on a cashless basis, there were no proceeds to the company. No Series A warrants were exercised, however the reset provisions increased the amount of Series A warrants such that 3,443,461 are outstanding at an exercise price of $3.22.

 

10

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

The fair value of the liability classified warrants was estimated using the Black-Scholes option pricing model. This method of valuation involves using inputs such as the fair value of our common stock, historical volatility, the contractual term of the warrants, risk-free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 2 measurement (see Note 6).

 

2026 Private Placement Warrants

 

Of the warrants to purchase 71,300,000 shares of common stock issued in the July 2026, August 2026 and September 2026 Offerings, warrants to purchase 68,698,111 shares were classified as liabilities through September 30, 2026: all 61,100,000 July 2026 Offering warrants and7,598,111 August 2026 Offering warrants. The Company did not have sufficient authorized and unissued shares of common stock to settle them under its sequencing policy, which reclassifies instruments to liabilities beginning with the earliest-issued instrument. The remaining401,889 August 2026 Offering warrants and all of the September 2026 Offering warrants were classified in stockholders’ equity. The liability-classified warrants were measured at fair value at issuance and remeasured at September 30, 2026, with changes in fair value recognized in change in fair value of derivative financial instruments—warrants. The warrants classified as liabilities at issuance were recorded at their fair value of $2,374,316, and the warrants reclassified after issuance were reclassified from stockholders’ equity at their fair value on the reclassification dates of $2,300,181, with the offset to additional paid-in capital. The fair value of the warrants was estimated using the Black-Scholes option pricing model, a Level 2 measurement. At issuance, the assumptions were a stock price of $0.072, an expected term of 5.0 years, a risk-free interest rate of 4.40% and expected volatility of 165.5%. The dividend yield was nil. On October 1, 2026, the Company’s authorized common stock increased to 750,000,000 shares, and the liability-classified warrants were reclassified to stockholders’ equity (see Note 12).

 

The following assumptions were used to measure warrant liabilities at period end.

 

  September 30,  December 31, 
  2026  2025 
Stock price $0.11  $0.06 
Expected warrant term (years)  3.3-4.9 years   4.2 years 
Risk-free interest rate  5.0-5.1%  3.64%
Expected volatility  175.6-199.19%  151.25%
Dividend yield  —   — 

 

The warrant to purchase 12,500,000 shares of common stock issued to Gravitas (see Note 5) cannot be exercised until stockholders approve an increase in the Company’s authorized shares. Because the holder cannot require the Company to deliver shares before that approval, the warrant remains classified in stockholders’ equity.

 

The following table sets forth the components of changes in our derivative financial instruments liability balance for the nine months ended September 30, 2026.

 Schedule of Derivative Liabilities at Fair Value

Date Number of
Warrants
Outstanding
  

Derivative
Instrument

Liability

 
Balance of derivative liability at December 31, 2025  3,477,775  $103,022 
Issuance of warrants classified as liabilities  68,698,111   4,674,497 
Change in fair value of warrants  —   3,088,277 
Balance of derivative liability at September 30, 2026  72,175,886   7,865,796 

 

5.Notes Payable

 

On March 15, 2025, the Company entered into a one-year Directors and Officers Liability Insurance agreement for $656,178. The Company made a down payment of $130,000, with the remaining balance financed with a third-party over the following ten months at an annual percentage rate of 7.30%. Beginning April 2025, the Company made 10 monthly payments of $54,394, and the last payment was made in January 2026.At the end of September 30, 2026, there was no outstanding balance on this note payable.

 

On September 3, 2026, the Company entered into a convertible note purchase agreement (the “Convertible Note”) with Gravitas Capital LP pursuant to which the Company issued a $500,000 secured convertible note along with a warrant to purchase 12,500,000 shares of Common Stock (the “Gravitas Warrant”). The Convertible Note bears interest at 8% per annum, payable in kind and has a maturity date of September 3, 2027. The Convertible Note is convertible at any time on or after September 3, 2026 contingent upon stockholder approval of an increase in the authorized shares of the Company’s Common Stock at the option of Gravitas at a conversion price of $0.04 per share. The Gravitas Warrant is exercisable on or after September 3, 2026 upon stockholder approval of an increase in the authorized shares of the Company Common Stock at an exercise price of $0.06 per share. In addition, the Company and Gravitas entered into a convertible note security agreement pursuant to which the Convertible Note is secured by all of the assets of the Company.

 

The Company evaluated the Convertible Note and Gravitas Warrant under ASC 480, Distinguishing Liabilities from Equity, ASC 815, Derivatives and Hedging, and ASC 470-20, Debt with Conversion and Other Options. The Gravitas Warrant is a freestanding financial instrument that is equity-classified. The proceeds of $500,000 were allocated between the Convertible Note and Gravitas Warrant based on their relative fair value, resulting in a debt discount of $208,358. Issuance costs of $10,000 were allocated $5,833 to the Convertible Note, as a reduction of its carrying amount, and $4,167 to the Gravitas Warrant, as a reduction of additional paid-in capital. The debt discount and issuance costs are amortized to interest expense over the term of the Convertible Note using the effective interest method. As of September 30, 2026, the Convertible Note had a carrying amount of $296,623, net of unamortized debt discount and issuance costs of $203,377, and accrued paid-in-kind interest of $2,959, for a total of $299,582. Interest expense on the Convertible Note, including amortization of the debt discount was $13,773 for the three and nine months ended September 30, 2026.

 

11

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

6.Fair Value Measurements

 

The following table presents our liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy at September 30, 2026 and December 31, 2025.

 

 Schedule of Liabilities Measured and Recognized at Fair Value on a Recurring Basis

Description Fair value  (Level 1)  (Level 2)  (Level 3) 
  Fair Value Measurement at Reporting Date Using 
Description Fair value  (Level 1)  (Level 2)  (Level 3) 
As of September 30, 2026:                
Derivative liabilities related to warrants $7,865,796  $—  $7,865,796  $— 
                 
As of December 31, 2025:                
Derivative liabilities related to warrants $103,022  $—  $103,022  $— 

 

The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative financial instruments—warrants in our consolidated statement of operations. See Note 4 for a rollforward of the derivative liability for the nine months ended September 30, 2026.

 

7.Accrued Liabilities

 

The following table presents our accrued liabilities at September 30, 2026 and December 31, 2025.

 Schedule of Accrued Liabilities

  September 30,
2026
  December 31,
2025
 
       
Payroll related $371,712  $29,172 
Accrued taxes  127,263   — 
Other  136,180   48,335 
Total accrued expenses $635,155  $77,507 

 

8.Accounting for Share-Based Payments

 

On June 3, 2013, we adopted the 2013 Equity Incentive Plan (the 2013 Plan), which expired in June 2023 and we are no longer making grants under it. Stock options granted under the 2013 Plan typically vested after three years of continuous service from the grant date and had a contractual term of ten years.

 

In April 2023, our board of directors approved the 2023 Omnibus Equity Incentive Plan (the 2023 Plan), which became effective in June 2023 upon stockholder approval. The 2023 Plan allowed for the grant of up to 10,000 awards for the purpose of attracting, motivating and retaining employees (including officers), non-employee directors and non-employee consultants. On June 17, 2026 and August 27, 2026, the shareholders approved amendments to the 2023 Plan to increase the total shares of common stock reserved for issuance under the 2023 Plan to an aggregate of 8,000,000 and 18,000,000, respectively. As of September 30, 2026, we had 11,420,970 awards available for grant from the 2023 Plan.

 

12

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

We classify stock-based compensation expense in our consolidated statement of operations in the same way the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified. We recorded stock-based compensation expense as follows:

Schedule of Stock Based Compensation Expense 

  2026  2025  2026  2025 
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  2026  2025  2026  2025 
General and administrative $198,447  $—  $198,447  $20,783 
Research and development  47,190   —   47,190   — 
Total stock-based compensation expense $245,637  $—  $245,637  $20,783 

 

A summary of stock option activity under the 2013 Plan and 2023 Plan is presented as follows:

 Schedule of Stock Option Activity

  Number of Options  

Weighted

Average

Exercise Price

Per Share

  

Intrinsic

Value

  

Weighted

Average

Remaining

Contractual

Term

Balance outstanding, December 31, 2025  5,822  $356.90  $—  5.15 years
Granted  6,578,000   0.08       
Forfeited  (5,792) $349.46  $—   
Balance outstanding, September 30, 2026  6,578,030  $0.09  $—  9.89 years
Awards outstanding, vested awards and those expected to vest at September 30, 2026  2,018,280  $0.11  $—  3.03 years
Vested and exercisable at September 30, 2026  2,018,280  $0.11  $—  3.03 years

 

The weighted-average grant date fair value of stock options granted during the three and nine months ended September 30, 2026 was $0.07. There were no stock options granted during the three and nine months ended September 30, 2025. The total fair value of stock options vested during the three and nine months ended September 30, 2026 was approximately $0.1 million. The total fair value of stock options vested during the three and nine months ended September 30, 2025 was approximately $13,870. As of September 30, 2026, there was approximately $0.2 million in unrecognized compensation cost related to non-vested stock options outstanding, net of expected forfeitures.

 

9.Loss per Share

 

Basic and diluted net loss per common share was determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period.

 Schedule of Computation of Basic and Diluted Net Loss Per Share

Basic and diluted net loss per common share: 2026  2025  2026  2025 
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
 
Basic and diluted net loss per common share: 2026  2025  2026  2025 
Numerator:                
Net loss $(4,582,920) $(472,506) $(6,641,948) $(7,620,965)
Denominator:                
Weighted average common shares outstanding  71,137,656   11,620,317   36,100,383   8,653,428 
Net loss per share of common stock—basic and diluted $(0.06) $(0.04) $(0.18) $(0.88)

 

13

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

The following outstanding securities at September 30, 2026 and 2025 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive due to net loss:

 Schedule of Outstanding Securities Excluded from Computation of Basic and Diluted Weighted Shares Outstanding

  2026  2025 
  Nine Months Ended
September 30,
 
  2026  2025 
Common shares issuable for:        
Series A preferred stock  3   3 
Series C preferred stock  16   16 
Stock options  6,578,030   7,813 
Warrants – liability classified  58,675,886   3,477,775 
Warrants – equity classified  28,601,889   1,795 

Convertible note (convertible upon stockholder approval)

  12,573,975   — 
Total  106,429,799   3,487,402 

 

10.Commitments and Contingencies

 

Legal Proceedings

 

We are involved in various legal proceedings. Significant judgment is required to determine both the likelihood and the estimated amount of a loss related to such matters. Additionally, while any litigation contains an element of uncertainty, we have at this time no reason to believe that the outcome of such proceedings or claims will have a material adverse effect on our consolidated financial condition or results of operations.

 

14

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Employment Agreements

 

On May 5, 2026, we entered into an employment agreement with each of Vincent LoPriore, our Executive Chairman (the “LoPriore Employment Agreement”) and Gary Stetz, our former Chief Executive Officer and current Chief Financial Officer (the “Stetz Employment Agreement”). In addition, on August 1, 2026, we entered into an employment agreement with Sireesh Appajosyula, our former Chief Operating Officer and current Chief Executive Officer (the “Appajosyula Employment Agreement”).

 

The LoPriore Employment Agreement shall continue for a period of five years and, thereafter, shall automatically renew for successive one-year terms unless either party provides the other party with written notice of non-renewal at least 60 days prior to the last day of the then current term. Pursuant to the LoPriore Employment Agreement, Mr. LoPriore shall: (i) receive a base salary of $280,000 per year, which may be increased by the Board; (ii) be eligible to receive an annual bonus equal to 50% of his then base salary based upon the achievement of Company and individual targets to be established by the Board, in its sole discretion; (iii) shall be eligible to receive equity-based compensation awards as determined by the Company; (iv) receive reimbursement of reasonable business expenses; and (v) receive such other benefits that the Company may make available to its senior executives from time to time along with vacation, sick and holiday pay in accordance with the Company’s policies established and in effect from time to time. In addition, Mr. LoPriore received a $50,000sign-on bonus.

 

In the event Mr. LoPriore’s employment is terminated by the Company other than as a result of his death or Disability and other than for Cause, or if Mr. LoPriore terminates his employment for Good Reason (as defined in the LoPriore Employment Agreement), then, in addition to accrued compensation, the Company shall (i) continue to pay Mr. LoPriore’s base salary and provide health benefits for a period of 12 months following the termination date or, in the case of benefits, such time as Mr. LoPriore receives equivalent coverage and benefits under plans and programs of a subsequent employer; and (ii) provide such other or additional benefits, if any, as may be provided under applicable employee benefit plans, programs and/or arrangements of the Company (other than any severance plans or programs). In addition, all unvested time-based equity awards (including Restricted Shares and Stock Options) shall be immediately and fully accelerated and become vested. Moreover, Stock Options that have vested as of the termination date shall remain exercisable until the earlier of (i) 60 months following such termination and (ii) the expiration date of the Stock Option.

 

The Stetz Employment Agreement shall continue for a period of five years and, thereafter, shall automatically renew for successive one year terms unless either party provides the other party with written notice of non-renewal at least 60 days prior to the last day of the then current term. Pursuant to the Stetz Employment Agreement, Mr. Stetz shall: (i) receive a base salary of $250,000 per year, which may be increased by the Board; (ii) be eligible to receive an annual bonus equal to 50% of his then base salary based upon the achievement of Company and individual targets to be established by the Board, in its sole discretion; (iii) shall be eligible to receive equity-based compensation awards as determined by the Company; (iv) receive reimbursement of reasonable business expenses; and (v) receive such other benefits that the Company may make available to its senior executives from time to time along with vacation, sick and holiday pay in accordance with the Company’s policies established and in effect from time to time. In addition, Mr. Stetz received a $50,000 sign-on bonus.

 

In the event Mr. Stetz’s employment is terminated by the Company other than as a result of his death or Disability and other than for Cause, or if Mr. Stetz terminates his employment for Good Reason (as defined in the Stetz Employment Agreement), then, in addition to accrued compensation, the Company shall (i) continue to pay Mr. Stetz’s base salary and provide health benefits for a period of 12 months following the termination date or, in the case of benefits, such time as Mr. Stetz receives equivalent coverage and benefits under plans and programs of a subsequent employer; and (ii) provide such other or additional benefits, if any, as may be provided under applicable employee benefit plans, programs and/or arrangements of the Company (other than any severance plans or programs). In addition, all unvested time-based equity awards (including Restricted Shares and Stock Options) shall be immediately and fully accelerate and become vested. Moreover, Stock Options that have vested as of the termination date shall remain exercisable until the earlier of (i) 60 months following such termination and (ii) the expiration date of the Stock Option.

 

The Appajosyula Employment Agreement shall continue for a period of five years and, thereafter, shall automatically renew for successive one year terms unless either party provides the other party with written notice of non-renewal at least 60 days prior to the last day of the then current term. Pursuant to the Appajosyula Employment Agreement, Dr. Appajosyula shall: (i) receive a base salary of $220,000per year, which may be increased by the Board; (ii) be eligible to receive an annual bonus equal to 50% of his then base salary based upon the achievement of Company and individual targets to be established by the Board, in its sole discretion; (iii) shall be eligible to receive equity-based compensation awards as determined by the Company; (iv) receive reimbursement of reasonable business expenses; and (v) receive such other benefits that the Company may make available to its senior executives from time to time along with vacation, sick and holiday pay in accordance with the Company’s policies established and in effect from time to time. In addition, Dr. Appajosyula received a $50,000 sign-on bonus.

 

In the event Dr. Appajosyula’s employment is terminated by the Company other than as a result of his death or Disability and other than for Cause, or if Dr. Appajosyula terminates his employment for Good Reason (as defined in the Appajosyula Employment Agreement), then, in addition to accrued compensation, the Company shall (i) continue to pay Dr. Appajosyula’s base salary and provide health benefits for a period of 12 months following the termination date or, in the case of benefits, such time as Dr. Appajosyula receives equivalent coverage and benefits under plans and programs of a subsequent employer; and (ii) provide such other or additional benefits, if any, as may be provided under applicable employee benefit plans, programs and/or arrangements of the Company (other than any severance plans or programs). In addition, all unvested time-based equity awards (including Restricted Shares and Stock Options) shall be immediately and fully accelerate and become vested. Moreover, Stock Options that have vested as of the termination date shall remain exercisable until the earlier of (i) 60 months following such termination and (ii) the expiration date of the Stock Option.

 

On March 16, 2026, Dr. Kaouthar Lbiati, the Chief Executive Officer of Hepion Pharmaceuticals, Inc. (the “Company”) informed the Board of Directors (the “Board”) of the Company that she was resigning as Chief Executive Officer for personal reasons, effective immediately.

 

On April 13, 2026 (the “Separation Date”), the Company entered into a separation agreement with Dr. Lbiati pursuant to which, among other things, she was paid (i) $225,000, (ii) $30,625 representing the pro-rata portion of her potential cash bonus and (iii) reimbursement of her COBRA payments for 6 months.

 

Further, pursuant to the separation agreement, Dr. Lbiati agreed to a general release and confidentiality. Also on April 13, 2026, Dr. Lbiati resigned as a director of the Company.

 

Operating Lease

 

On September 3, 2026, the Company entered into a lease agreement (the “Red Bank Lease”) with West Street Ventures LLC (the “Landlord”) for office space. The Landlord is owned by the Company’s Executive Chairman (see Note 11 – Related Party). The lease expires on August 31, 2029 and base rent is $2,000 per month with no escalation. The Company paid a refundable security deposit of $2,000 which is included in other noncurrent assets. The Company has an option to extend the lease for five years, at base rent adjusted for cumulative changes in the Consumer Price Index. The Company concluded that exercise of the renewal option is not reasonably certain, so the renewal period is excluded from the lease term.

 

The lease is classified as an operating lease and the Company recognized a right-of-use asset of $62,499 and lease liability of $60,499, using an incremental borrowing rate of 10%. Operating lease cost for the three and nine months ended September 30, 2026 was $2,000 and the weighted-average remaining lease term is 2.9 years. At September 30, 2026, the right-of-use asset was $61,003 and the operating lease liability was $61,003, of which $18,953 is classified as current.

 

As of September 30, 2026, future minimum payments under the Red Bank lease were:

 Schedule of Future Minimum Payments

Year ending December 31, Amount 
2026 $6,000 
2027  24,000 
2028  24,000 
2029  16,000 
Total undiscounted lease payments  70,000 
Less: imputed interest  (8,997)
Present value of operating lease liability $61,003 

 

15

 

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

11.Related Party

 

The Company’s related party transactions are described below.

 

Vincent LoPriore, the Company’s Executive Chairman and a director, is the principal of Gravitas Capital LP (“Gravitas Capital”), a stockholder of the Company. Mr. LoPriore also controls President Street Global LLC (“PSG”) and West Street Ventures LLC (“West Street”), the entity from which the Company leases its office space. During the periods presented, Mr. LoPriore and certain other officers and directors of the Company also served as officers or directors of, and held ownership interests in, Gravitas Life Sciences, LLC (“GLS”) through its sole member, Gravitas Collective Corporation (“Gravitas Collective”). The Company acquired GLS from Gravitas Collective on October 6, 2026 (see Note 12).

 

Convertible Note and Warrant

 

As described in Note 5, on September 3, 2026, the Company issued the $500,000Convertible Note and the Gravitas Warrant to purchase 12,500,000shares of common stock to Gravitas Capital. At September 30, 2026, the carrying amount of the Convertible Note was $299,582, including paid-in-kind interest of $2,959, and the Company recognized interest expense of $13,773on the Convertible Note for the three and nine months ended September 30, 2026.

 

Loan to GLS

 

On September 8, 2026, in connection with the then-proposed acquisition of GLS, the Company loaned $500,000 to GLS under a promissory note bearing interest at 10% per annum and repayable on demand (the “Interim Note”). At the time of the loan, Mr. LoPriore was Executive Chairman of GLS and, together with other officers of the Company, a stockholder of Gravitas Collective. At September 30, 2026, the principal of the Interim Note of $500,000 is included in related party receivable and accrued interest of $3,194 is included in prepaid expenses and other current assets. Following the acquisition of GLS on October 6, 2026, the Interim Note is an intercompany balance that is eliminated in consolidation.

 

Officers Shared with GLS

 

During the three and nine months ended September 30, 2026, Mr. LoPriore; Sireesh Appajosyula, the Company’s Chief Operating Officer since August 1, 2026; Chase LoPriore, the Company’s Vice President, Corporate Strategy since July 20, 2026 and a family member of Mr. LoPriore; and Bobbi Fox-Caminiti, Director of Operations, were also employed by GLS, and Gary Stetz, the Company’s Chief Executive Officer, was a director of GLS. Each of Mr. LoPriore, Dr. Appajosyula, Mr. C. LoPriore and Ms. Fox-Caminiti devoted approximately 50% of his or her working time to the Company and was compensated separately by the Company and by GLS under their respective employment agreements, each of which permits the executive to serve other companies. The condensed consolidated financial statements include only compensation paid or payable by the Company, which totaled $314,670 and $466,593 for these individuals for the three and nine months ended September 30, 2026, respectively. These individuals’ employment agreements with GLS were terminated, and they resigned as officers of GLS, upon the closing of the GLS acquisition.

 

Financial Advisory Services

 

The Company engaged PSG as its exclusive financial advisor in connection with the acquisition of GLS. The engagement was approved on behalf of the Company by disinterested directors of the Board. Upon the closing of the acquisition, the Company paid PSG a success fee of $212,500, equal to 5% of the purchase price, in October 2026. The Company engaged PSG on July 30, 2026 at a monthly fee of $65,000 for ongoing financial advisory services, which is included in general and administrative expenses. PSG also provides corporate advisory services to GLS under an agreement dated February 1, 2026, which was accelerated upon closing of the acquisition of GLS. The Company agreed to pay the accelerated fee of $600,000 during the fourth quarter of 2026.

 

Office Lease

 

The Company leases office space under the Red Bank Lease from West Street, an entity owned by related parties Sireesh Appajosyula, Chase LoPriore, Vincent LoPriore, and Gary Stetz II, that commenced on September 3, 2026 at a monthly rent of $2,000. Rent expense under the lease was $2,000 for the three and nine months ended September 30, 2026 and the Company has paid a security deposit of $2,000, which is included in other assets (see Note 10 – Commitments and Contingencies).

 

12.Subsequent Events

 

On October 1, 2026, the Company filed a Certificate of Amendment to its Certificate of Incorporation increasing its authorized common stock from 120,000,000 shares to 750,000,000 shares. As a result, the Company has sufficient authorized and unissued shares to settle the liability-classified warrants issued in the July 2026 and August 2026 Offerings. On October 1, 2026, these 68,698,111warrants were remeasured at their fair value of approximately $6.6 million and reclassified from derivative financial instruments—warrants to additional paid-in capital. Total stockholders’ equity after giving effect to the reclassified warrants, on October 1, 2026, was $3.6 million.

 

On October 6, 2026, the Company entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Gravitas Life Sciences, LLC, a Delaware limited liability company (“GLS”), and Gravitas Collective Corp, a Delaware corporation and the sole member of GLS, pursuant to which the Company agreed to acquire all of the issued and outstanding membership interests (the “Purchase Securities”) of GLS (the “GLS Transaction”). Pursuant to the Purchase Agreement, Gravitas Collective Corp. sold the Purchase Securities to the Company in exchange for the right to receive (i) $2,000,000in cash and (ii) 25,000,000shares of the Company’s common stock (the “Stock Consideration”), par value $0.0001per share. The Purchase Agreement contained a cap providing that in no event will the aggregate number of shares of common stock exceed 19.99% of the Company’s outstanding shares of common stock immediately following issuance, with any resulting reduction in shares to be settled in an equitable cash payment. The Company paid an additional $135,000 to Gravitas Collective Corp. The shares of common stock comprising the Stock Consideration are subject to a lock-up restricting transfer until the earlier of (i) the six-month anniversary of the closing date on October 6, 2026 and (ii) the date the shares are registered for resale under an effective registration statement.

 

In connection with the GLS Transaction, Gravitas Collective Corp. and Canton Strategic Holdings, Inc. (“Canton”) entered into a partial payoff confirmation and note assignment dated October 6, 2026 (the “Payoff Letter”), relating to an unsecured promissory note dated July 17, 2026 between GLS and Canton (the “Canton Note”). Pursuant to the Payoff Letter, the Company paid Canton $1,000,000 and GLS paid $125,000 out of the $2,000,000 Purchase Consideration, as a mandatory prepayment of a portion of the outstanding principal balance of the Canton Note. Upon Canton’s receipt of payment, GLS and Gravitas Collective Corp.’s obligations under the Canton Note were deemed satisfied, discharged and terminated and were assigned to the Company.

 

Vincent LoPriore, Gary Stetz, Sireesh Appajosyula, and Chase LoPriore, each a current director of the Company, are officers of GLS and shareholders of Gravitas Collective Corp. Accordingly, the GLS Transaction constitutes a related party transaction. In light of their respective affiliations with GLS and Gravitas Collective Corp., each of Mr. V. LoPriore, Mr. Stetz, Dr. Appajosyula, and Mr. C. LoPriore recused himself from deliberation and voting on the matter.

 

On October 9, 2026, the Board appointed Dr. Appajosyula as Chief Executive Officer and Mr. Stetz as Chief Financial Officer. 

 

16

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion should be read in conjunction with our condensed consolidated financial statements and other financial information appearing elsewhere in this quarterly report. In addition to historical information, the following discussion and other parts of this quarterly report contain forward-looking statements. You can identify these statements by forward-looking words such as “plan,” “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. Forward-looking statements include information concerning possible or assumed future business success or financial results. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Accordingly, we do not undertake any obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

 

The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties set forth under “Risk Factors” in our Annual Report on Form 10-K as of and for the year ended December 31, 2025 filed with the United States Securities and Exchange Commission (“SEC”) on March 12, 2026, as well as under “Risk Factors” within this Form 10-Q. Accordingly, to the extent that this Report contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of us, please be advised that our actual financial condition, operating results and business performance may differ materially from that projected or estimated by us in forward-looking statements, and you should not unduly rely on such statements.

 

Overview

 

Hepion Pharmaceuticals, Inc. (we, our, or us) is a medical diagnostic company headquartered in Red Bank, New Jersey, that was previously focused on the development of drug therapy for treatment of chronic liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), was being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease.

 

On February 25, 2026, we entered into an intellectual property license agreement with Cirna Diagnostics, LLC (“Cirna”) pursuant to which we licensed certain liver disease diagnostic assets from Cirna. We paid an upfront payment of $70,000 during the nine months ended September 30, 2026 and could pay up to $2,350,000 in milestone payments, up to $4,500,000 in sales milestone payments and a royalty payment on net sales in the low single digits. We accounted for this transaction as an asset acquisition. The total upfront consideration of $70,000 was allocated to purchased in-process research and development, and was expensed upon the completion of the transaction. We did not recognize any contingent consideration (milestone payments) given the low probability of meeting those targets. Royalties will be recognized when earned.

 

During 2026, we entered into employment agreements with each of Vincent LoPriore, our Executive Chairman, Gary Stetz, our former Interim Chief Executive Officer, appointed as Chief Financial Officer in October 2026, and Sireesh Appajosyula, our former Chief Operating Officer, appointed as Chief Executive Officer in October 2026.

 

Recent Developments

 

On October 1, 2026, we filed a Certificate of Amendment to our Certificate of Incorporation increasing our authorized common stock from 120,000,000 shares to 750,000,000 shares.

 

On October 6, 2026, we entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Gravitas Life Sciences, LLC, a Delaware limited liability company (“GLS”), and Gravitas Collective Corp, a Delaware corporation and the sole member of GLS, pursuant to which the Company agreed to acquire all of the issued and outstanding membership interests (the “Purchase Securities”) of GLS (the “GLS Transaction”). Pursuant to the Purchase Agreement, Gravitas Collective Corp. sold the Purchase Securities to the Company in exchange for the right to receive (i) $2,000,000 in cash and (ii) 25,000,000 shares of the Company’s common stock (the “Stock Consideration”), par value $0.0001 per share. The Purchase Agreement contained a cap providing that in no event will the aggregate number of shares of common stock exceed 19.99% of the Company’s outstanding shares of common stock immediately following issuance, with any resulting reduction in shares to be settled in an equitable cash payment. The Company paid an additional $135,000 to Gravitas Collective Corp. The shares of common stock comprising the Stock Consideration are subject to a lock-up restricting transfer until the earlier of (i) the six-month anniversary of the closing date on October 6, 2026 and (ii) the date the shares are registered for resale under an effective registration statement.

 

GLS is a clinical-stage biotechnology company developing therapeutic candidates in immunology and inflammation. On November 3, 2023, GLS entered into a patent license agreement (the “Avior License Agreement”) with Avior Inc. d/b/a Avior Bio, LLC (“Avior”). The agreement grants GLS an exclusive, sublicensable, worldwide right and license to Licensed Patent Rights and Licensed Technology to develop, make, use, sell, import, export and commercialize GV104 (formerly TH104), and to practice the Licensed Technology in connection with the foregoing, each as defined in that agreement. In February 2023 the U.S. Food and Drug Administration (“FDA”) approved an investigational new drug (“IND”) application for GV104, a transmucosal buccal film of nalmefene. Nalmefene is an opioid antagonist first approved in the United States in 1995 and is marketed in injectable and limited nasal presentations. The film adheres to the buccal mucosa, and the drug is absorbed across the mucosa potentially without first-pass hepatic metabolism.

 

In April 2024 GLS submitted a pre-investigational new drug meeting request to the FDA for the proposed indication of temporary prophylaxis of respiratory and/or central nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids (“PrHPO”). The approval pathway GLS proposed is a 505(b)(2) New Drug Application (“NDA”) for GV104 relying on the FDA’s prior findings for Revex® (nalmefene hydrochloride injection). The FDA responded in March 2025 stating that “additional clinical studies do not appear to be necessary to define the prophylactic dosing window at this time.” GLS deprioritized a previous clinical program for pruritus in primary biliary cholangitis and intends to continue to rely on the existing active IND for PrHPO development.

 

The clinical bridging study for the 505(b)(2) application compared a 16 mg GV104 buccal film against 1 mg intravenous nalmefene in a randomized two-way crossover in 20 healthy subjects, reporting an absolute bioavailability of 45.9 percent, a median Tmax of 2.0 hours and a mean half-life of 14 hours. The FDA identified extractables and leachables studies and elemental impurities as required, and further nonclinical studies as possibly needed to qualify new excipients and impurities, as part of the Chemistry, Manufacturing and Controls (“CMC”) package required for an NDA. The FDA confirmed that nonclinical and chemistry data on file under the existing IND may be cross-referenced to the PrHPO application. In August 2025 GLS submitted a Type D briefing package containing a pharmacokinetic-pharmacodynamic modeling plan in place of further clinical work. In October 2025 the FDA endorsed the model and requested a validated worst-case fentanyl challenge dose. In July 2026 GLS submitted the completed cardiac-arrest simulation.

 

On October 26, 2026, we announced that the FDA had provided written responses to the July 2026 briefing package, re-affirming the overall modeling approach and providing comments on the model structure, the presentation of results and the fentanyl challenge simulations, which the FDA stated would improve the Company’s ability to demonstrate long-term prophylactic protection. In the simulation as submitted, a single 16 mg GV104 buccal film taken at least 15 minutes before exposure prevented every simulated fentanyl-induced cardiac arrest in 200 virtual subjects at lethal fentanyl doses, with protection predicted at a median of 10 to 15 minutes after dosing. GLS believes each comment is addressable within its existing modeling program and intends to submit its response promptly; the revised analysis may produce different results.

 

GLS is also developing GV104 for the treatment of gambling disorder, a psychiatric condition with no FDA-approved pharmacotherapy. On October 19, 2026, we announced that the FDA’s Division of Psychiatry had issued written responses to GLS’s Type B pre-IND meeting request for GV104 in gambling disorder, addressing the 505(b)(2) regulatory pathway, the nonclinical package and the design of a planned Phase 2 study. The FDA confirmed that GLS may cross-reference the nonclinical and CMC sections of the existing IND, stated that the nonclinical studies on file appear potentially sufficient to support 12-week clinical dosing in a Phase 2 study, and stated that the planned Phase 2 proof-of-concept design and proposed primary endpoint are, in general, appropriate. GLS intends to file an IND for GV104 in gambling disorder in 2027; the final Phase 2 design remains subject to change following IND review. FDA feedback at the pre-IND stage is advisory and not binding on the Agency.

 

17

 

GLS intends to file an NDA for PrHPO after conducting CMC work covering the manufacturing process, quality control and product stability for the buccal film. No clinical study is in progress or scheduled for the dosing window and the extractables and leachables studies the FDA identified require commercial-scale registration batches, which GLS intends to begin producing in 2027.

 

On September 11, 2024, GLS entered into a Patent License Agreement (the “Intract Agreement”) with Intract Pharma Limited (“Intract”). Under that agreement GLS exclusively licensed GV023 (formerly INT-023/TH023), an oral formulation of infliximab, an anti-tumor necrosis factor-alpha (“TNF-α”) monoclonal antibody. Infliximab is a purified, recombinant DNA-derived chimeric IgG monoclonal antibody containing murine and human components that inhibits TNF-α. The agreement grants global development and commercialization rights outside South Korea to Intract’s Soteria® and Phloral® delivery platforms and includes an existing supply agreement for infliximab. Phloral® is an enteric coating that releases on a pH signal and on a microbiota-enzymatic signal. Soteria® protects the antibody through gastric transit and limits proteolytic degradation. GV023 contains no device component and is currently in preclinical development. A minipig study reported proximal colon tissue exposure with minimal systemic exposure and the MHRA has provided written scientific advice, applicable in the United Kingdom, that no further preclinical studies are required and has accepted the existing infliximab safety data. Initiation of a first-in-human study in Australia or the European Union requires the corresponding national process, on which GLS intends to obtain further guidance in 2027 planning CMC and first-in-man programs.

 

FINANCIAL OPERATIONS OVERVIEW

 

From inception through September 30, 2026, we have an accumulated deficit of $252.7 million, and we have not generated any revenue from operations.

 

CRITICAL ACCOUNTING ESTIMATES

 

Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, costs and expenses, income taxes and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.

 

During the nine months ended September 30, 2026, there were no significant changes to our critical accounting estimates from those described in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in the Annual Report on Form 10-K for the year ended December 31, 2025.

 

RECENT ACCOUNTING PRONOUNCEMENTS

 

Please refer to Note 3 of Notes to Condensed Consolidated Financial Statements, Recent Accounting Pronouncements, in this Quarterly Report on Form 10-Q.

 

RESULTS OF OPERATIONS

 

Comparison of the three months ended September 30, 2026 and 2025:

 

  Three Months Ended
September 30,
    
  2026  2025  Change 
Revenues $—  $—  $— 
Costs and Expenses:            
Research and development  134,654   —   134,654 
General and administrative  1,415,892   527,902   887,990 
Asset impairment loss  —   —   — 
Total operating expenses  1,550,546   527,902   1,022,644 
Loss from operations  (1,550,546)  (527,902)  (1,022,644)
             
Other income (expense):            
Interest income (expense)  (3,494)  8,116   (11,610)
Other income (expense), net  6,255   —   6,255 
Change in fair value of derivative financial instruments—warrants  (3,035,135)  47,280   (3,082,415)
Net loss $(4,582,920) $(472,506) $(4,110,414)

 

We had no revenues during the three months ended September 30, 2026 and 2025, because we have not commercialized any of our products and we do not expect to have such products for several years, if at all.

 

Research and development expenses for the three months ended September 30, 2026 and 2025 was approximately $0.1 million and $0, respectively. The increase in research and development expense in 2026 is primarily related to an increase in research and development personnel during 2026.

 

General and administrative expenses for the three months ended September 30, 2026 and 2025 was approximately $1.4 million and $0.5 million, respectively. The increase of $0.9 million was primarily due to approximately $0.5 million increase in personnel costs of our general and administrative employees, $0.1 million in professional fees, $0.2 million in non-cash stock-based compensation for our general and administrative personnel and $0.1 million increase in public company costs.

 

Other income (expense), net for the three months ended September 30, 2026 consists of a gain of $21,799 from the return of 346,020 shares of Common Stock pursuant to the New Day Termination Agreement, offset by $15,544 of offering costs allocated to the liability-classified warrants issued in the July 2026 Offering. The change in fair value of derivative financial instruments – warrants of approximately $3.0 million for the three months ended September 30, 2026 is non-cash. It reflects the increase in the fair value of outstanding warrants, including the July 2026 and August 2026 Offering warrants classified as liabilities, primarily driven by the increase in our stock price.

 

18

 

Comparison of the nine months ended September 30, 2026 and 2025:

 

  Nine Months Ended
September 30,
    
  2026  2025  Change 
Revenues $—  $—  $— 
Costs and Expenses:            
Research and development  255,572   445,512   (189,940)
General and administrative  3,304,974   2,705,750   599,224 
Asset impairment loss  —   402,746   (402,746)
Total operating expenses  3,560,546   3,554,008   6,538
Loss from operations  (3,560,546)  (3,554,008)  (6,538)
             
Other income (expense):            
Interest income (expense)  620   (11,829)  26,222 
Other income (expense), net  6,255   —   6,255 
Change in fair value of derivative financial instruments—warrants  (3,088,277)  (4,055,128)  966,851 
Net loss $(6,641,948) $(7,620,965) $979,017 

 

We had no revenues during the nine months ended September 30, 2026 and 2025, because we have not commercialized any of our products and we do not expect to have such products for several years, if at all.

 

Research and development expenses for the nine months ended September 30, 2026 and 2025 were approximately $0.3 million and $0.4 million, respectively. The decrease in research and development expense in 2026 is primarily related to the purchase of in-process research and development related to the New Day asset acquisition in 2025, partially offset by Cirna license fees incurred in 2026 and an increase in research and development personnel.

 

General and administrative expenses for the nine months ended September 30, 2026 and 2025 were approximately $3.3 million and $2.7 million, respectively. The increase of approximately $0.6 million was primarily due to an increase of $1.1 million in personnel costs of our general and administrative personnel and $0.2 million in non-cash stock-based compensation for our general and administrative personnel. These increases were partially offset by a $0.6 million decrease in legal and accounting fees and $0.1 million decrease in public company costs.

 

Asset impairment loss for the nine months ended September 30, 2026 and 2025 was $0 and $0.4 million, respectively. The decrease in asset impairment loss is related to the asset from the New Day license agreement that was fully impaired in prior year.

 

The change in fair value of derivative financial instruments – warrants for the nine months ended September 30, 2026 of approximately $3.1 million is non-cash and reflects the increase in the fair value of outstanding warrants, including the July 2026 and August 2026 Offering warrants classified as liabilities, primarily driven by the increase in our stock price. For the nine months ended September 30, 2025, the change in fair value of $4.1 million related to the 2025 Series A and Series B warrants. Other income (expense), net for the nine months ended September 30, 2026 consists of the $21,799 gain on the return of common stock, offset by $15,544 of offering costs allocated to the liability-classified warrants. 

 

19

 

Liquidity and Capital Resources

 

Sources of Liquidity

 

We have funded our operations through September 30, 2026 primarily through the issuance of convertible preferred stock, warrants, the issuance and sale of shares of our common stock, and subsequent issuances of shares of our common stock through at-the market offerings.

 

On April 21, 2026, we entered into securities purchase agreements with certain accredited investors pursuant to which the Company agreed to sell and issue an aggregate of 17,500,000 shares of Common Stock in a private placement offering at an offering price of $0.04 per share for gross proceeds of $700,000. The Offering closed on April 21, 2026.

 

On July 31, 2026, we entered into securities purchase agreements with certain accredited investors pursuant to which the Company agreed to sell and issue an aggregate of 61,100,000 shares of Common Stock and warrants to purchase 61,100,000 shares of Common Stock, in a private placement offering at an offering price of $0.05 per share for gross proceeds of approximately $3.1 million. The warrants are exercisable at an exercise price of $0.06 per share for five years from the date of issuance. The July 2026 Offering closed on August 3, 2026. In addition, during the third quarter of 2026, we sold an aggregate of 10,200,000 shares of Common Stock and warrants to purchase 10,200,000 shares of Common Stock in the August 2026 Offering and the September 2026 Offering at an offering price of $0.05 per share for aggregate gross proceeds of approximately $0.5 million.

 

Future Funding Requirements

 

We have no products approved for commercial sale in the United States. To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and clinical trials of our former product candidates. As a result, we are not profitable and have incurred losses in each period since our inception in 2013. As of September 30, 2026, we had an accumulated deficit of $252.7 million. We expect to continue to incur significant losses for the foreseeable future.

 

We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders’ equity and working capital.

 

We will require additional financing and a failure to obtain this necessary capital could force us to delay, limit, reduce or terminate our operations.

 

Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our non-replicating and replicating technologies and our product candidates derived from these technologies. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the development of acquired assets in connection with our strategic alternatives strategy. In addition, other unanticipated costs may arise.

 

20

 

Our future capital requirements depend on many factors, including:

 

 ●the scope, progress, results and costs of researching and developing our current and future product candidate and programs, and of conducting preclinical studies and clinical trials;
   
 ●the number and development requirements of other product candidates that we may pursue, and other indications for our current product candidate that we may pursue;
   
 ●the timing of, and the costs involved in, obtaining regulatory and marketing approvals and developing our ability to establish sales and marketing capabilities, if any, for our future product candidates we develop if clinical trials are successful;
   
 ●our ability to establish and maintain collaborations, strategic licensing or other arrangements and the financial terms of such agreements;
   
 ●the cost of commercialization activities for our future product candidates that we may develop, whether alone or with a collaborator;
   
 ●the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;
   
 ●the timing, receipt and amount of sales of, or royalties on, our future products, if any; and

 

A change in the outcome of any of these or other variables with respect to the development of any of our future product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will need additional funds to meet operational needs and capital requirements associated with such operating plans.

 

The condensed consolidated financial statements as of September 30, 2026 have been prepared under the assumption that we will continue as a going concern within one year after the financial statements are issued. Due to our accumulated deficit and our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

21

 

We will be required to raise additional capital to continue to fund operations. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to (i) acquire new product candidates; or (ii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.

 

Cash Flows

 

The following table summarizes our cash flows for the following periods:

 

  Nine Months Ended
September 30,
 
  2026  2025 
Net cash provided by (used in):        
Operating activities $(1,697,270) $(2,938,745)
Investing activities  (500,000)  (132,117)
Financing activities  4,624,554   4,985,532 

 

As of September 30, 2026, we had working capital of $3.8 million compared to working capital of $2.8 million as of December 31, 2025. The increase of $1.0 million in working capital is primarily due to proceeds from equity issuances during the period, partially offset by operating costs incurred during the period.

 

Operating Activities:

 

Net cash used in operating activities was $1.7 million for the nine months ended September 30, 2026, consisting primarily of our net loss of $6.6 million, offset by change in prepaid expenses of $1.1 million, non-cash stock-based compensation of $0.2 million, change in accounts payable and accrued expense of $0.6 million, non-cash change in fair value of derivative financial instruments – warrants of $3.1 million and $15,544 of offering costs allocated to warrant liabilities.

 

Net cash used in operating activities was $2.9 million for the nine months ended September 30, 2025, consisting primarily of our net loss of $7.6 million, adjusted for non-cash charges of $4.5 million, including $4.1 million in change in fair value of derivative warrants and $0.4 million in asset impairment loss. Changes in operating assets and liabilities increased by $0.2 million.

 

Investing Activities:

 

Net cash used in investing activities was $0.5 million for the nine months ended September 30, 2026, related to a related party loan receivable. Net cash used in investing activities was $0.1 million for the nine months ended September 30, 2025 related to the acquisition of licenses from New Day Diagnostics.

 

Financing Activities:

 

Net cash provided by financing activities was $4.6 million for the nine months ended September 30, 2026, consisting of net proceeds of $4.3 million from equity offerings and $0.5 million of proceeds from a note payable, offset by payment of notes payable of $0.1 million and equity issuance costs of $0.1 million.

 

Net cash provided by financing activities was $5.0 million for the nine months ended September 30, 2025, due primarily to $9.0 million in net proceeds received from the exercise of the warrants and equity issuance offset by $3.2 million payment on notes payable and equity issuance costs of $0.8 million.

 

22

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Based on an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) required by paragraph (b) of Rule 13a-15 or Rule 15d-15, as of September 30, 2026, our Principal Executive Officer and Principal Financial Officer have concluded that due to the material weaknesses in our internal control over financial reporting noted below, our disclosure controls and procedures were not effective. 

 

 ●Due to cost-cutting measures, the Company’s control environment was ineffective as they did not maintain a sufficient complement of personnel to execute controls as designed including the absence of proper segregation of duties. Such impacted controls include indirect controls affecting risk assessment, information & communication, and monitoring components of COSO along with certain control activities including both business process controls and information technology general controls.
 ●Lack of proper design and implementation of controls over formal review, approval, and evaluation of non-core, complex accounting transactions.
 ●Lack of proper design and implementation of certain controls over the income tax provision and management’s review of the income tax provision. The Company utilized a third-party to assist in the preparation of the tax provision. Specifically, the Company did not sufficiently design and implement controls related to the completeness and accuracy of certain aspects of the tax provision and the completeness and accuracy of income tax disclosures.

 

Remediation of Material Weaknesses

 

We are committed to the remediation of the material weaknesses described above, as well as the continued improvement of our internal control over financial reporting. During the nine months ended September 30, 2026 and through the date of this report, we implemented the following remedial actions:

 

●Segregation of duties and review of key workpapers. We reassigned responsibilities among our finance and accounting personnel to improve segregation of duties. Key account reconciliations, journal entries and financial reporting workpapers are now prepared by one individual and reviewed and approved by our Chief Financial Officer, with evidence of review retained.
●Accounts payable and cash disbursements. We implemented a multi-level review and approval process for accounts payable and payments. Invoices are approved by the responsible budget owner before payment. Payments are reviewed and approved by more than one individual, and the person who prepares a payment is not the person who approves or releases it.
●Complex accounting transactions. We engaged a third-party accounting specialist to assist management in evaluating and documenting the accounting for non-routine and complex transactions, including warrants, convertible debt and business combinations. Technical accounting memoranda are prepared for these transactions and reviewed by our Chief Financial Officer before the related amounts are recorded.
●Board oversight. We expanded our Board of Directors to seven members, which strengthens oversight of financial reporting and internal control.

 

While these actions represent progress, the material weaknesses will not be considered remediated until the enhanced controls have operated for a sufficient period of time and management has concluded, through testing, that they are designed and operating effectively.

 

Changes in Internal Control over Financial Reporting

 

Except as noted above, there have been no changes in our internal controls over financial reporting during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

23

 

PART II. OTHER INFORMATION

 

ITEM 1A. RISK FACTORS

 

There have been no material changes from the risk factors disclosed in our Form 10-K for the year ended December 31, 2025.

 

ITEM 5. Other Information

 

During the three months ended September 30, 2026, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement, and/or any non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K).

 

ITEM 6. EXHIBITS

 

2.1 Membership Interest Purchase Agreement, dated as of October 6, 2026 by and among Hepion Pharmaceuticals, Inc., Gravitas Life Sciences, LLC and Gravitas Collective Corp. (incorporated by reference to Exhibit 2.1 to Form 8-K filed on October 9, 2026)
3.1 Certificate of Amendment to Certificate of Incorporation of Hepion Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on October 2, 2026)
4.1 Form of Convertible Note (incorporated by reference to Exhibit 4.1 to Form 8-K filed on September 8, 2026).
4.2 Form of Warrant (incorporated by reference to Exhibit 4.2 to Form 8-K filed on September 8, 2026)
10.1 Form of Convertible Note Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on September 8, 2026)
10.2 Form of Convertible Note Security Agreement (incorporated by reference to Exhibit 10.2 to Form 8-K filed on September 8, 2026).
10.3 Employment Agreement between Sireesh Appajosyula and Hepion Pharmaceuticals, Inc. dated August 1, 2026
31.1 Certification of Chief Executive Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.
31.2 Certification of Chief Financial Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.
32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB Inline XBRL Taxonomy Label Linkbase
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase
104 Cover Page Interactive Data File (formatted as Inline XBRL in Exhibit 101)

 

24

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 HEPION PHARMACEUTICALS, INC. (Registrant)
   
Date: November 13, 2026By:/s/ Sireesh Appajosyula
  Sireesh Appajosyula
  Chief Executive Officer
  (Principal Executive Officer)

 

25